HIV-1 diversity in the envelope glycoproteins: Implications for viral entry inhibition

Viruses

Volumn 5, Issue 2, 2013, Pages 595-604

  Araújo, Leonardo Augusto Luvison ^a   Almeida, Sabrina E M ^a  

^a Fundacao Estadual de Producao e Pesquisa em Saude   (Brazil)

Author keywords

Diversity; Entry inhibitors; Envelope; HIV 1

Indexed keywords

VIRUS ENVELOPE PROTEIN;

GENE MUTATION; GENE SEQUENCE; GENETIC VARIABILITY; INFECTION RESISTANCE; INFECTION RISK; MICROBIAL DIVERSITY; MUTATIONAL ANALYSIS; NONHUMAN; NUCLEOTIDE SEQUENCE; PROTEIN CONFORMATION; PROTEIN FUNCTION; PROTEIN PROTEIN INTERACTION; REVIEW; VIRUS ENTRY; VIRUS INHIBITION; VIRUS MUTATION;

EID: 84873735544     PISSN: 19994915     EISSN: None     Source Type: Journal    
DOI: 10.3390/v5020595     Document Type: Review

References (40)

1. Taylor, B.S.; Sobieszczyk, M.E.; McCutchan, F.E.; Hammer, S.M. The challenge of HIV-1 subtype diversity. N Engl. J. Med. 2008, 358, 1590-1602.
2. Sharp, P.M.; Hahn, B.H. Origins of HIV and the AIDS Pandemic. Cold Spring Harbor Laboratory Press 2011, 1, 1.
3. Herbeck, J.T.; Nickle, D.C.; Learn, G.H.; Gottlieb, G.S.; Curlin, M.E.; Heath, L.; Mullins, J.I. Human immunodeficiency virus type 1 env evolves toward ancestral states upon transmission to a new host. J. Virol. 2006, 80, 1637-1644.
4. Yang, Z.; Chakrabarti, B.K.; Xu, L.; Welcher, B.; Kong, W.; Leung, K.; Panet, A.; Mascola, J.R.; Nabel, G.J. Selective modification of variable loops alters tropism and enhances immunogenicity of human immunodeficiency virus type 1 envelope. J. Virol. 2004, 78, 4029-4036.
5. Wainberg, M.A.; Brenner, B.G. Role of HIV subtype diversity in the development of resistance to antiviral drugs. Viruses 2010, 2, 2493-2508.
6. Wilen, C.B.; Tilton, J.C.; Doms, R.W. Molecular mechanisms of HIV entry. Viral Molecular Machines 2012, 726, 223-242.
7. Sundaravaradan, V.; Das, S.R.; Ramakrishnan, R.; Sehgal, S.; Gopalan, S.; Ahmad, N.; Jameel, S. Role of HIV-1 subtype C envelope V3 to V5 regions in viral entry, coreceptor utilization and replication efficiency in primary T-lymphocytes and monocyte-derived macrophages. Virol. J. 2007, 4, 126.
8. Caffrey, M. HIV envelope: Challenges and opportunities for development of entry inhibitors. Trends Microbiol. 2011, 19, 191-197.
9. Lobritz, M.A.; Ratcliff, A.N.; Arts, E.J. HIV-1 entry, inhibitors, and resistance. Viruses 2010, 2, 1069-1105.
10. Choisy, M.; Woelk, C.H.; Guégan, J.F.; Robertson, D.L. Comparative study of adaptive molecular evolution in different human immunodeficiency virus groups and subtypes. J. Virol. 2004, 78, 1962-1970.
11. Travers, S.A.A.; O'Connell, M.J.; McCormack, G.P.; McInerney, J.O. Evidence for heterogeneous selective pressures in the evolution of the env gene in different human immunodeficiency virus type 1 subtypes. J. Virol. 2005, 79, 1836-1841.
12. Klevytska, A.M.; Mracna, M.R.; Guay, L.; Becker-Pergola, G.; Furtado, M.; Zhang, L.; Jackson, J.B.; Eshleman, S.H. Analysis of length variation in the V1-V2 region of env in nonsubtype B HIV type 1 from Uganda. AIDS Res. Hum. Retrovir. 2002, 18, 11, 791-796.
13. Curlin, M.E.; Zioni, R.; Hawes, S.E.; Liu, Y.; Deng, W.; Gottlieb, G.S.; Zhu, T.; Mullins, J.I. HIV-1 envelope subregion length variation during disease progression. PLoS Pathogens 2010, 6, e1001228.
14. Cormier, E.G.; Dragic, T. The crown and stem of the V3 loop play distinct roles in human immunodeficiency virus type 1 envelope glycoprotein interactions with the CCR5 coreceptor. J. Virol. 2002, 76, 8953-8957.
15. Sander, O.; Sing, T.; Sommer, I.; Low, A.J.; Cheung, P.K.; Harrigan, P.R.; Lengauer, T.; Domingues, F.S. Structural descriptors of gp120 V3 loop for the prediction of HIV-1 coreceptor usage. PLoS Computational Biology 2007, 3, e58.
16. Gaschen, B.; Taylor, J.; Yusim, K.; Foley, B.; Gao, F.; Lang, D.; Novitsky, V.; Haynes, B.; Hahn, B.H.; Bhattacharya, T. Diversity considerations in HIV-1 vaccine selection. Science 2002, 296, 2354-2360.
17. Gnanakaran, S.; Lang, D.; Daniels, M.; Bhattacharya, T.; Derdeyn, C.A.; Korber, B. Clade-specific differences between human immunodeficiency virus type 1 clades B and C: Diversity and correlations in C3-V4 regions of gp120. J. Virol. 2007, 81, 4886-4891.
18. Rong, R.; Gnanakaran, S.; Decker, J.M.; Bibollet-Ruche, F.; Taylor, J.; Sfakianos, J.N.; Mokili, J.L.; Muldoon, M.; Mulenga, J.; Allen, S. Unique mutational patterns in the envelope α2 amphipathic helix and acquisition of length in gp120 hypervariable domains are associated with resistance to autologous neutralization of subtype C human immunodeficiency virus type 1. J. Virol. 2007, 81, 5658-5668.
19. Patel, M.B.; Hoffman, N.G.; Swanstrom, R. Subtype-specific conformational differences within the V3 region of subtype B and subtype C human immunodeficiency virus type 1 Env proteins. J. Virol. 2008, 82, 903-916.
20. Holguín, A.; de Arellano, E.R.; Soriano, V. Amino acid conservation in the gp41 transmembrane protein and natural polymorphisms associated with enfuvirtide resistance across HIV-1 variants. AIDS Res. Hum. Retrovir. 2007, 23, 1067-1074.
21. Holguín, A.; Faudon, J.L.; Labernardière, J.L.; Soriano, V. Susceptibility of HIV-1 non-B subtypes and recombinant variants to Enfuvirtide. J. Clin. Virol. 2007, 38, 176-180.
22. Sanders, R.W.; Korber, B.; Lu, M.; Berkhout, B.; Moore, J.P. Mutational analyses and natural variablility of the gp41 ectodomain. HIV Sequence Compendium 2002, 2002, 43-68.
23. Razzolini, F.; Vicenti, I.; Saladini, F.; Micheli, V.; Romano, L.; Cargnel, A.; Zazzi, M. Natural variability in the HR-1 and HR-2 domains of HIV type 1 gp41 from different clades circulating in Italy. AIDS Res. Hum. Retrovir. 2007, 23, 558-563.
24. Kuhmann, S.E.; Pugach, P.; Kunstman, K.J.; Taylor, J.; Stanfield, R.L.; Snyder, A.; Strizki, J.M.; Riley, J.; Baroudy, B.M.; Wilson, I.A. Genetic and phenotypic analyses of human immunodeficiency virus type 1 escape from a small-molecule CCR5 inhibitor. J. Virol. 2004, 78, 2790-2807.
25. Ogert, R.A.; Wojcik, L.; Buontempo, C.; Ba, L.; Buontempo, P.; Ralston, R.; Strizki, J.; Howe, J.A. Mapping resistance to the CCR5 co-receptor antagonist vicriviroc using heterologous chimeric HIV-1 envelope genes reveals key determinants in the C2-V5 domain of gp120. Virology 2008, 373, 387-399.
26. Putcharoen, O.; Lee, S.H.; Henrich, T.J.; Hu, Z.; Vanichanan, J.; Coakley, E.; Greaves, W.; Gulick, R.M.; Kuritzkes, D.R.; Tsibris, A. HIV-1 Clinical isolates resistant to CCR5 antagonists exhibit delayed entry kinetics that are corrected in the presence of drug. Science Signaling 2012, 86, 1119.
27. Anastassopoulou, C.G.; Ketas, T.J.; Sanders, R.W.; Klasse, P.J.; Moore, J.P. Effects of sequence changes in the HIV-1 gp41 fusion peptide on CCR5 inhibitor resistance. Virology 2012, 482, 86-97.
28. Araújo, L.A.L.; Junqueira, D.M.; de Medeiros, R.M.; Matte, M.C.C.; Almeida, S.E.M. Naturally occurring resistance mutations to HIV-1 entry inhibitors in subtypes B, C, and CRF31_BC. J. Clin. Virol. 2012, 54, 6-10.
29. Gonzalez, S.; Gondwe, C.; Tully, D.C.; Minhas, V.; Shea, D.; Kankasa, C.; M'soka, T.; Wood, C. Short communication: Antiretroviral therapy resistance mutations present in the HIV type 1 subtype C pol and env regions from therapy-naive patients in Zambia. AIDS Res. Hum. Retrovir. 2010, 26, 795-803.
30. Geretti, A.M.; Easterbrook, P. Antiretroviral resistance in clinical practice. Int. J. STD AIDS, 2006, 12, 145-153.
31. Ray, N.; Blackburn, L.A.; Doms, R.W. HR-2 mutations in human immunodeficiency virus type 1 gp41 restore fusion kinetics delayed by HR-1 mutations that cause clinical resistance to enfuvirtide. J. Virol. 2009, 83, 2989-2995.
32. Xu, L.; Pozniak, A.; Wildfire, A.; Stanfield-Oakley, S.A.; Mosier, S.M.; Ratcliffe, D.; Workman, J.; Joall, A.; Myers, R.; Smit, E. Emergence and evolution of enfuvirtide resistance following long-term therapy involves heptad repeat 2 mutations within gp41. Antimicrob. Agents Chemother. 2005, 49, 1113-1119.
33. Baatz, F.; Nijhuis, M.; Lemaire, M.; Riedijk, M.; Wensing, A.M.J.; Servais, J.Y.; van Ham, P.M.; Hoepelman, A.I.M.; Koopmans, P.P.; Sprenger, H.G. Impact of the HIV-1 env genetic context outside HR1-HR2 on resistance to the fusion inhibitor enfuvirtide and viral infectivity in clinical isolates. PloS One 2011, 6, e21535.
34. Labrosse, B.; Morand-Joubert, L.; Goubard, A.; Rochas, S.; Labernardière, J.L.; Pacanowski, J.; Meynard, J.L.; Hance, A.J.; Clavel, F.; Mammano, F. Role of the envelope genetic context in the development of enfuvirtide resistance in human immunodeficiency virus type 1-infected patients. J. Virol. 2006, 80, 8807-8819.
35. Reeves, J.D.; Gallo, S.A.; Ahmad, N.; Miamidian, J.L.; Harvey, P.E.; Sharron, M.; Pöhlmann, S.; Sfakianos, J.N.; Derdeyn, C.A.; Blumenthal, R. Sensitivity of HIV-1 to entry inhibitors correlates with envelope/coreceptor affinity, receptor density, and fusion kinetics. Proc. Natl. Acad. Sci. 2002, 99, 16249-16254.
36. Derdeyn, C.A.; Decker, J.M.; Sfakianos, J.N.; Wu, X.; O'Brien, W.A.; Ratner, L.; Kappes, J.C.; Shaw, G.M.; Hunter, E. Sensitivity of human immunodeficiency virus type 1 to the fusion inhibitor T-20 is modulated by coreceptor specificity defined by the V3 loop of gp120. J. Virol. 2000, 74, 8358-8367.
37. Derdeyn, C.A.; Decker, J.M.; Sfakianos, J.N.; Zhang, Z.; O'Brien, W.A.; Ratner, L.; Shaw, G.M.; Hunter, E. Sensitivity of human immunodeficiency virus type 1 to fusion inhibitors targeted to the gp41 first heptad repeat involves distinct regions of gp41 and is consistently modulated by gp120 interactions with the coreceptor. J. Virol. 2001, 75, 8605-8614.
38. Heil, M.L.; Decker, J.M.; Sfakianos, J.N.; Shaw, G.M.; Hunter, E.; Derdeyn, C.A. Determinants of human immunodeficiency virus type 1 baseline susceptibility to the fusion inhibitors enfuvirtide and T-649 reside outside the peptide interaction site. J. Virol. 2004, 78, 7582-7589.
39. Cilliers, T.; Patience, T.; Pillay, C.; Papathanasopoulos, M.; Morris, L. Sensitivity of HIV type 1 subtype C isolates to the entry inhibitor T-20. AIDS Res. Hum. Retrovir. 2004, 20, 477-482.
40. Yu, X.; Yuan, L.; Huang, Y.; Xu, W.; Fang, Z.; Liu, S.; Shao, Y.; Jiang, S.; Ma, L. Susceptibility of HIV-1 subtypes B′, CRF07_BC and CRF01_AE that are predominantly circulating in China to HIV-1 entry inhibitors. PloS One 2011, 6, e17605.